UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of: July, 2004
Commission File Number: 000-50393
NEUROCHEM INC.
275 Armand-Frappier Boulevard
Laval, Quebec
H7V 4A7
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40 F. Form 20-F | | Form 40-F [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Yes | | No [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):
Yes | | No [X]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g-3 under the Securities Exchange Act of 1934.
Yes | | No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
SIGNATURES:
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
NEUROCHEM INC.
July 15, 2004
By: /s/ David Skinner
---------------------------------------
David Skinner
Director, Legal Affairs,
General Counsel and Corporate Secretary
NEUROCHEM INC.
275 Armand-Frappier Blvd.
[NEUROCHEM LOGO] Laval, Quebec, Canada H7V 4A7
- -------------------------------------------------------------------------------
NEUROCHEM TO PRESENT FINDINGS AT THE 9TH INTERNATIONAL
CONFERENCE ON ALZHEIMER'S DISEASE AND RELATED DISORDERS
PRESENTATION OF INTERIM CLINICAL DATA ON ALZHEMED(TM)
FOR THE TREATMENT OF ALZHEIMER'S DISEASE
MONTREAL, JULY 15, 2004 -- Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced
today that it will make two oral presentations and will have two posters at the
9th International Conference on Alzheimer's Disease and Related Disorders (ICAD)
in Philadelphia starting Sunday, July 18, 2004.
Paul Aisen, MD, Professor of Neurology and Medicine at Georgetown University
Medical Center in Washington, D.C., and principal investigator in the United
States for the Phase III clinical trial on Alzhemed(TM) has also been invited to
present the latest interim clinical results of the Phase II open label extension
study on Alzhemed(TM) for the treatment of Alzheimer's Disease (AD) at a press
conference organized by ICAD, presented by the Alzheimer's Association. The
press conference will feature innovative anti-amyloid therapeutic programs
developed by Neurochem and two other companies in the field of AD. The press
conference will be held on Wednesday, July 21, at 12:30 PM, EDT in Room 307B of
the Pennsylvania Convention Center in Philadelphia, Pennsylvania. More than
4,500 experts from around the world are expected to attend ICAD.
ORAL PRESENTATIONS
WHAT: ALZHEMED(TM) INTERIM CLINICAL RESULTS IN MILD-TO-MODERATE AD PATIENTS
(OPEN-LABEL EXTENDED STUDY)
WHO: Dr. Paul Aisen, Professor of Neurology and Medicine at Georgetown
University Medical Center in Washington, D.C. and principal
investigator in the United States for the Phase III study on
Alzhemed(TM)
WHEN: Sunday, July 18
4:00 PM
EVENT: Therapeutics-1
LOCATION: Room 204 ABC
Pennsylvania Convention Center
WHAT: TARGETING GAGS FOR TREATMENT OF ALZHEIMER'S DISEASE within the
Symposium: CURRENT PROGRESS ON DEVELOPMENT OF THERAPEUTIC
STRATEGIES BASED UPON THE AMYLOID HYPOTHESIS
WHO: Francine Gervais, Ph.D., Vice-President, Research and Development,
Neurochem Inc.
WHEN: Monday, July 19
5:30 PM
EVENT: Current Progress on Development of Therapeutic Strategies Based
Upon the Amyloid Hypothesis
LOCATION: Ballroom A/B
Pennsylvania Convention Center
POSTER PRESENTATIONS
WHAT: "AGE MODULATES THE VULNERABILITY OF RAT NEURONAL CULTURES TO
A(BETA)-INDUCED CELL DEATH"
WHO: Morissette, Celine, et al.
WHEN: Tuesday, July 20
12:30 PM-2:45 PM
LOCATION: Hall B
Pennsylvania Convention Center
Abstract #191
2
WHAT: "ZWITTERIONIC COMPOUNDS PROMOTE CONFORMATIONALLY AND
MORPHOLOGICALLY UNIQUE CHANGES IN THE A(BETA) PEPTIDE"
WHO: McLaughlin, Richard, et al.
WHEN: Wednesday, July 21
12:30 PM-2:45 PM
LOCATION: Hall B
Pennsylvania Convention Center
Abstract #397
Neurochem will be on-site at its corporate booth (#109) from Monday, July 19th,
through to Wednesday, July 21st, to meet anyone interested in learning more
about the Company's programs and to answer any questions.
ABOUT NEUROCHEM
Neurochem is focused on the development and commercialization of innovative
therapeutics for neurological disorders. The Company's pipeline of proprietary,
disease-modifying, oral products addresses critical unmet medical needs.
Fibrillex(TM), designated as an orphan drug and as a Fast Track Product
candidate, is also part of a Continuous Marketing Applications Pilot 2 program
and is currently in a Phase II/III clinical trial for the treatment of AA
Amyloidosis. Alzhemed(TM), for the treatment of Alzheimer's disease, is in a
Phase III clinical trial and Cerebril(TM), for the prevention of Hemorrhagic
Stroke caused by Cerebral Amyloid Angiopathy, has completed a Phase II clinical
trial.
TO CONTACT NEUROCHEM
For additional information on Neurochem and its drug development programs,
please call the North American toll-free number 1-877-680-4500 or visit our
website at: www.neurochem.com.
Certain statements contained in this news release, other than statements of fact
that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and uncertainties,
known and unknown, many of which are beyond Neurochem's control. Such risks
include but are not limited to: the impact of general economic conditions,
general conditions in the pharmaceutical industry, changes in the regulatory
environment in the jurisdictions in which Neurochem does business, stock market
volatility, fluctuations in costs, and changes to the competitive environment
due to consolidation as well as other risks included in public filings of
Neurochem. Consequently, actual future results may differ materially from the
anticipated results expressed in the forward-looking statements. The reader
should not place undue reliance on the forward-looking statements included in
this news release. These statements speak only as of the date made and Neurochem
is under no obligation and disavows any intention to update or revise such
statements as a result of any event, circumstances or otherwise.
FOR FURTHER INFORMATION, PLEASE CONTACT:
3
Lise Hebert, Ph.D.
Vice President, Corporate Communications
lhebert@neurochem.com
Tel: (450) 680-4500
Fax: (450) 680-4501
4